The Enterprise Value as of November 2024 (TTM) for Erasca, Inc. (ERAS) is 747.42M

According to Erasca, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 747.42M. This represents a change of 69.57% compared to the average of 440.76M of the last 4 quarters.

Erasca, Inc. (ERAS) Historical Enterprise Value (quarterly & annually)

How has ERAS Enterprise Value performed in the past?

The mean historical Enterprise Value of Erasca, Inc. over the last ten years is 1.23B. The current 747.42M Enterprise Value has changed 5.97% with respect to the historical average. Over the past ten years (40 quarters), ERAS's Enterprise Value was at its highest in in the September 2021 quarter at 1.68B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Erasca, Inc. (ERAS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Erasca, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Erasca, Inc. (ERAS) Average Enterprise Value

How has ERAS Enterprise Value performed in the past?

The current Enterprise Value of Erasca, Inc. (ERAS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Erasca, Inc. (ERAS) Enterprise Value vs. Peers

How is ERAS’s Enterprise Value compared to its peers?

Erasca, Inc.’s Enterprise Value is greater than Century Therapeutics, Inc. (104.89M), greater than NGM Biopharmaceuticals, Inc. (69.72M), less than Keros Therapeutics, Inc. (1.75B), greater than Monte Rosa Therapeutics, Inc. (439.72M), less than Gracell Biotechnologies Inc. (5.61B), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Design Therapeutics, Inc. (290.40M), less than Edgewise Therapeutics, Inc. (3.01B), greater than C4 Therapeutics, Inc. (307.45M), greater than Mineralys Therapeutics, Inc. (523.81M), greater than Cullinan Oncology, Inc. (630.54M), greater than Sana Biotechnology, Inc. (551.82M), greater than Olema Pharmaceuticals, Inc. (468.89M), greater than aTyr Pharma, Inc. (138.44M), greater than Zentalis Pharmaceuticals, Inc. (229.32M), greater than Relay Therapeutics, Inc. (692.53M), greater than Stoke Therapeutics, Inc. (457.69M), less than Pliant Therapeutics, Inc. (770.48M), greater than Black Diamond Therapeutics, Inc. (139.97M), less than Arvinas, Inc. (1.69B),

Build a custom stock screener for Erasca, Inc. (ERAS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Erasca, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Erasca, Inc. (ERAS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Erasca, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.